No Data
No Data
Express News | Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024
Executive Reshuffles: INTC, ZS, ETSY and SEDG
Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Express News | Beam Therapeutics: All 7 Patients Treated With Beam-101 Achieved Durable Increases in Fetal Hemoglobin, Reductions in Sickle Hemoglobin
Express News | Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at Ash Annual Meeting
Express News | Beam Therapeutics: Initial Safety Profile Consistent With Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation
No Data